Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Trump Says Anthropic No Longer Seen as National Security Threat 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Minneapolis, MN, Jan. 06, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that it will be presenting at the 8th Annual Biotech Showcase(TM) to be held January 11-13, 2016 in San Francisco, California.
Event: Biotech Showcase 2016
Location: Parc 55 Hilton Hotel, San Francisco
Date: Tuesday January 12, 2016
Time: 11:30 AM (PST)
BioSig Executive Chairman, Ken Londoner will deliver the Company’s corporate presentation and discuss recent business highlights. To arrange a meeting with management, please contact Robert Haag at [email protected] or 1-866-976-4784.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
- Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
- HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. [email protected] 917-370-9817 Robert Haag Managing Partner IRTH Communications [email protected] 866-976-4784
